Christoph U. Correll, MD

Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, German Center for Mental Health (DZPG), partner site Berlin, Germany

JCP
Consensus Statement

May 8, 2018

The authors of this consensus statement look at the history of the use of the Abnormal Involuntary Movement Scale in tardive dyskinesia studies and outline the challenges of using...
, , , et al
JCP
Academic Highlights

March 20, 2018

Read a study where experts review the prevalence, phenomenology, risk factors, and impact of Tardive Dyskinesia (TD).
,
JCP
Educational Activity

February 21, 2018

Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify...
,
JCP
Educational Activity

December 27, 2017

JCP
Original Research

November 14, 2017

Valbenazine, a VMAT2  inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study...
, , , et al
JCP
Letter to the Editor

October 25, 2017

, , , et al
JCP
Academic Highlights

October 10, 2017

Is your patient experiencing involuntary movements of the face, torso, or extremities? It could be tardive dyskinesia, a side effect of antipsychotic medications. Explore this CME Academic Highlights activity...
, ,
JCP
Article

September 5, 2017

Early treatment response in adults with acute mania is a good predictor of ultimate response and remission. Read this article by Xiao and colleagues to see if response to...
, , , et al
JCP
Original Research

August 23, 2017

When children as young as 3 years old are prescribed anticonvulsants, antipsychotics, or psychotropic polypharmacy for their first diagnosis of ADHD, what is the trajectory of treatment in subsequent...
, , , et al
JCP
Original Research

July 18, 2017

In 2015, the FDA removed WBC monitoring altogether and reduced the threshold for ANCs before interruption of clozapine treatment was required. The current study looks at almost 250 clozapine-treated...
, , , et al
JCP
Original Research

July 5, 2017

Antipsychotic medications are increasingly prescribed to treat depression. But is this use always warranted? Read the article by Gerhard and colleagues to learn how often antipsychotics are prescribed in...
, , , et al
JCP
Review Article

May 9, 2017

Want to do more than prescribe psychotropic medications for youth with disruptive behaviors? Read this systematic review for the latest research on how digitally-assisted parent training programs are being...
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe